. | Control . | Type 2 diabetic . |
---|---|---|
τV̇o2 (s) | 34.2 ± 8.2 | 43.8 ± 9.6* |
τHR (s) | 45.1 ± 15.9 | 51.2 ± 14.1 |
τ[HHb] (s) | 10.2 ± 4.4 | 8.8 ± 4.8 |
MRT [HHb] (s) | 17.8 ± 5.5 | 18.5 ± 4.6 |
τ1 Qm phase 1 (s) | 6.6 ± 2.8 | 5.1 ± 3.2 |
τ2 Qm phase 2 (s) | 32.0 ± 9.7 | 43.6 ± 12.9* |
MRT Qm (s) | 35.8 ± 10.7 | 47.7 ± 14.3* |
τV̇o2 (s) | 34.2 ± 8.2 | 43.8 ± 9.6* |
. | Control . | Type 2 diabetic . |
---|---|---|
τV̇o2 (s) | 34.2 ± 8.2 | 43.8 ± 9.6* |
τHR (s) | 45.1 ± 15.9 | 51.2 ± 14.1 |
τ[HHb] (s) | 10.2 ± 4.4 | 8.8 ± 4.8 |
MRT [HHb] (s) | 17.8 ± 5.5 | 18.5 ± 4.6 |
τ1 Qm phase 1 (s) | 6.6 ± 2.8 | 5.1 ± 3.2 |
τ2 Qm phase 2 (s) | 32.0 ± 9.7 | 43.6 ± 12.9* |
MRT Qm (s) | 35.8 ± 10.7 | 47.7 ± 14.3* |
τV̇o2 (s) | 34.2 ± 8.2 | 43.8 ± 9.6* |
Data are means ± SD. Refer to text for calculation of τ, τ1, τ2, and MRT. τV̇o2, time constant for V̇o2 kinetics; τHR, time constant for heart rate; τ[HHb], time constant for increase in [HHb]; τ1 Qm, time constant for phase 1 of Qm; τ2 Qm, time constant for phase 2 of Qm.
P < 0.05, type 2 diabetic versus control subjects.